150 related articles for article (PubMed ID: 11077037)
1. Angiotensin II type 1 receptor antagonists. Why do some of them produce insurmountable inhibition?
Vanderheyden PM; Fierens FL; Vauquelin G
Biochem Pharmacol; 2000 Dec; 60(11):1557-63. PubMed ID: 11077037
[TBL] [Abstract][Full Text] [Related]
2. A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists.
Vauquelin G; Morsing P; Fierens FL; De Backer JP; Vanderheyden PM
Biochem Pharmacol; 2001 Feb; 61(3):277-84. PubMed ID: 11172731
[TBL] [Abstract][Full Text] [Related]
3. Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors.
Vanderheyden PM; Fierens FL; De Backer J; Vauquelin G
Biochem Pharmacol; 2000 Apr; 59(8):927-35. PubMed ID: 10692557
[TBL] [Abstract][Full Text] [Related]
4. Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding.
Fierens FL; Vanderheyden PM; De Backer JP; Vauquelin G
Eur J Pharmacol; 1999 May; 372(2):199-206. PubMed ID: 10395100
[TBL] [Abstract][Full Text] [Related]
5. Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.
Vanderheyden PM; Fierens FL; De Backer JP; Fraeyman N; Vauquelin G
Br J Pharmacol; 1999 Feb; 126(4):1057-65. PubMed ID: 10193788
[TBL] [Abstract][Full Text] [Related]
6. Antagonist interaction with endogenous AT(1) receptors in human cell lines.
Verheijen I; Vanderheyden PM; De Backer JP; Bottari S; Vauquelin G
Biochem Pharmacol; 2002 Oct; 64(8):1207-14. PubMed ID: 12234601
[TBL] [Abstract][Full Text] [Related]
7. Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors.
Verheijen I; Fierens FL; Debacker JP; Vauquelin G; Vanderheyden PM
Fundam Clin Pharmacol; 2000; 14(6):577-85. PubMed ID: 11206708
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
Morsing P; Adler G; Brandt-Eliasson U; Karp L; Ohlson K; Renberg L; Sjöquist PO; Abrahamsson T
Hypertension; 1999 Jun; 33(6):1406-13. PubMed ID: 10373224
[TBL] [Abstract][Full Text] [Related]
9. Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cells.
Fierens F; Vanderheyden PM; De Backer JP; Vauquelin G
Eur J Pharmacol; 1999 Feb; 367(2-3):413-22. PubMed ID: 10079018
[TBL] [Abstract][Full Text] [Related]
10. A two-state model of antagonist-AT1 receptor interaction: further support by binding studies at low temperature.
Verheijen I; De Backer JP; Vanderheyden P; Vauquelin G
Biochem Pharmacol; 2003 Apr; 65(8):1339-41. PubMed ID: 12694874
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of angiotensin II-induced inositol phosphate production by triacid nonpeptide antagonists in CHO cells expressing human AT1 receptors.
Vanderheyden PM; Verheijen I; Fierens FL; DeBacker JP; Vauquelin G
Pharm Res; 2000 Dec; 17(12):1482-8. PubMed ID: 11303957
[TBL] [Abstract][Full Text] [Related]
12. Insurmountable AT(1) receptor antagonism: the need for different antagonist binding states of the receptor.
Vauquelin G; Fierens F; Verheijen I; Vanderheyden P
Trends Pharmacol Sci; 2001 Jul; 22(7):343-4. PubMed ID: 11460825
[No Abstract] [Full Text] [Related]
13. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
Montón M; Jiménez A; Núñez A; López-Blaya A; Farré J; Gómez J; Zalba LR; Sánchez de Miguel L; Casado S; López-Farré A
J Cardiovasc Pharmacol; 2000 Jun; 35(6):906-13. PubMed ID: 10836725
[TBL] [Abstract][Full Text] [Related]
14. Distinctions between non-peptide angiotensin II AT1-receptor antagonists.
Vauquelin G; Fierens FL; Verheijen I; Vanderheyden PM
J Renin Angiotensin Aldosterone Syst; 2001 Mar; 2(1_suppl):S24-S31. PubMed ID: 28095245
[TBL] [Abstract][Full Text] [Related]
15. The angiotensin AT(1) receptor antagonist irbesartan has near-peptide affinity and potently blocks receptor signaling.
Hines J; Fluharty SJ; Sakai RR
Eur J Pharmacol; 1999 Nov; 384(1):81-9. PubMed ID: 10611423
[TBL] [Abstract][Full Text] [Related]
16. In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan.
Fabiani ME; Dinh DT; Nassis L; Casley DJ; Johnston CI
Am J Hypertens; 2000 Sep; 13(9):1005-13. PubMed ID: 10981551
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist.
Maillard MP; Perregaux C; Centeno C; Stangier J; Wienen W; Brunner HR; Burnier M
J Pharmacol Exp Ther; 2002 Sep; 302(3):1089-95. PubMed ID: 12183667
[TBL] [Abstract][Full Text] [Related]
18. Effects of the insurmountable angiotensin AT1 receptor antagonist candesartan and the surmountable antagonist losartan on ischemia/reperfusion injury in rat hearts.
Wang QD; Sjöquist PO
Eur J Pharmacol; 1999 Sep; 380(1):13-21. PubMed ID: 10513555
[TBL] [Abstract][Full Text] [Related]
19. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor.
Ojima M; Inada Y; Shibouta Y; Wada T; Sanada T; Kubo K; Nishikawa K
Eur J Pharmacol; 1997 Jan; 319(1):137-46. PubMed ID: 9030909
[TBL] [Abstract][Full Text] [Related]
20. [Candesartan cilexetil: pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist].
Inada Y; Naka T
Nihon Yakurigaku Zasshi; 2000 Mar; 115(3):151-60. PubMed ID: 10876800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
